This is a preview of subscription content, log in via an institution to check access.
Reference
Zhang PF, et al. Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer. Tumori : 300891620916789, 30 Apr 2020. Available from: URL:http://dx.doi.org/10.1177/0300891620916789
Rights and permissions
About this article
Cite this article
Addition of fruquintinib to BSC for metastatic CRC not cost effective in China. PharmacoEcon Outcomes News 853, 3 (2020). https://doi.org/10.1007/s40274-020-6798-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6798-1